MRNA vaccine and preparation method thereof

Directly prepare DNA templates for mRNA vaccines through in vitro amplification technology, replacing the recombinant plasmid construction steps in traditional methods, solving the problems of long R&D cycle and high cost in the existing technology, and achieving rapid and effective mRNA vaccine preparation and novel models Protective antibody induction of coronavirus variants.

CN118924888APending Publication Date: 2024-11-12ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310781789.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2023-06-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

During the preparation of existing mRNA vaccines, there are steps such as recombinant plasmid construction, strain expansion and culture and plasmid extraction, which leads to a long R&D cycle, high cost, and reduced protective efficacy for the novel coronavirus mutant strain.

Method used

Using in vitro amplification technology to prepare DNA templates containing protective antigen RBD coding sequences from viral nucleic acid samples, prepare mRNA vaccines through in vitro transcription, replace the steps of antigen gene synthesis and recombinant plasmid construction in traditional methods, shorten the preparation time and increase efficiency.

Benefits of technology

The rapid preparation of mRNA vaccines has been achieved, shortened the preparation cycle from 12 days to 2 days, reduced costs, and effectively induced the production of specific IgG antibodies and neutralizing antibodies, against novel coronaviruses, pangolin coronaviruses and bat coronaviruses Variants such as viruses are protective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924888A_ABST
    Figure CN118924888A_ABST
Patent Text Reader

Abstract

The invention relates to the field of mRNA vaccines, and discloses a method for preparing an mRNA vaccine, which comprises the following steps: (1) amplifying a target gene through a first polymerase chain reaction and an optional second polymerase chain reaction to obtain an amplification product; (2) carrying out in-vitro transcription on the amplification product to obtain mRNA (messenger ribonucleic acid); (3) carrying out capping and tailing on the mRNA, so as to obtain modified mRNA; (4) assembling the modified mRNA and a carrier; wherein the final concentration of the upstream primer and the final concentration of the downstream primer in an amplification system are independently smaller than or equal to 5 mu M. According to the method for preparing the mRNA, the target gene does not need to be cloned to a vector and a linearized product does not need to be prepared, and the preparation time of the vaccine can be greatly shortened by using the method for preparing the mRNA vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of mRNA vaccines, and in particular to an mRNA vaccine and a preparation method thereof. Background Art

[0002] Since the outbreak of the novel coronavirus, the pneumonia epidemic has spread rapidly to many countries and regions around the world. At present, the novel coronavirus is still mutating and spreading, and a number of studies have confirmed that the protective efficacy of existing vaccines and antibodies against the novel coronavirus variants has been significantly reduced. In addition, the potential threat of pathogens such as pangolin coronavirus and bat-like coronavirus to human health cannot be ignored. In order to effectively respond to the epidemic of the above-mentioned new emerging pathogens or potentially threatening pathogens, it is crucial to develop a fast, efficient and universal key technology for vaccine development.

[0003] mRNA vaccines have the advantages of short R&D cycle, fast response speed, rapid production capacity expansion, and the ability to stimulate cellular and humoral immune responses at the same time. They are an emerging field and key research direction for the next generation of vaccine research and development. The preparation of mRNA vaccines mainly includes key links such as molecular design, antigen gene synthesis, recombinant plasmid construction, strain expansion culture, plasmid extraction, in vitro transcription template preparation, in vitro transcription and capping of mRNA, and preparation and identification of lipid nanoparticles. The construction of recombinant plasmids requires the preparation of vectors and target fragments, which are then connected and transformed into specific competent cells, and finally the correct monoclonal clones are selected. This process involves multiple steps, which will increase the cost of raw materials and time costs in the vaccine preparation process. DNA templates are directly amplified from viral nucleic acid samples through in vitro amplification technology for mRNA stock solution synthesis and vaccine preparation, which can replace key processes such as recombinant plasmid construction, strain expansion culture, and plasmid extraction, greatly shortening the preparation time of mRNA, while simplifying the vaccine production process and process.

[0004] Previous studies have shown that the receptor binding domain (RBD) located on the viral surface glycoprotein (S protein) can serve as a major antigen, effectively inducing the production of neutralizing antibodies in experimental animals and humans, and has been used in the design of a variety of candidate vaccines. Summary of the invention

[0005] The present invention uses an in vitro amplification method to prepare an in vitro transcription template, replacing the steps of recombinant plasmid construction and linearization product preparation in the traditional mRNA vaccine preparation process, and provides a rapid preparation method for mRNA vaccines based on in vitro amplification technology.

[0006] The primer pairs designed by the inventors of the present invention directly prepare DNA templates containing protective antigen (RBD) coding sequences from viral nucleic acid samples by in vitro amplification. The templates can be directly used for in vitro transcription to prepare mRNA stock solutions that can be translated into protective antigens. Subsequently, the mRNA molecules are capped, tailed, and packaged in lipid nanoparticles to complete vaccine preparation. Compared with traditional methods, it can replace antigen gene synthesis, recombinant plasmid construction, strain expansion culture, in vitro transcription templates, etc., greatly reducing the time cost of mRNA vaccine preparation.

[0007] The upstream primer of the first pair of primers includes the promoter (1-19), 5'UTR (20-62) and the signal peptide (63-126), and the downstream primer includes the 3'UTR (1-118). At the same time, the inventors optimized the primer concentration to be less than or equal to 5 μM, which can effectively amplify the target sequence from different viral nucleic acid samples.

[0008] In summary, the first aspect of the present invention provides a method for preparing an mRNA vaccine, the method comprising:

[0009] (1) amplifying the target gene by a first polymerase chain reaction and an optional second polymerase chain reaction to obtain an amplified product;

[0010] (2) transcribing the amplified product in vitro to obtain mRNA;

[0011] (3) capping and tailing the mRNA to obtain modified mRNA;

[0012] (4) assembling the modified mRNA with the vector;

[0013] Wherein, the final concentrations of the upstream primer and the downstream primer in the amplification system are independently less than or equal to 5 μM.

[0014] The second aspect of the present invention provides an mRNA vaccine prepared by the above method.

[0015] Through the above technical scheme, the method for preparing mRNA vaccines provided by the present invention does not require cloning the target gene into a vector and preparing a linearized product, and the target gene can be directly amplified from various forms of nucleic acid samples such as RNA and DNA, thereby shortening the vaccine preparation cycle (the traditional method takes about 12 days, and the method of the present invention only takes about 2 days). In addition, in the method of the present invention, mRNA vaccines for different pathogens can be prepared by changing the primer pair sequence. More preferably, the primer pairs designed by the present invention can specifically amplify multiple coronavirus RBD fragments through sequence analysis. The mRNA preparation prepared by this method can induce the production of specific IgG antibodies and neutralizing antibodies in experimental animals, especially different variants of the new coronavirus, pangolin coronavirus and bat coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is the electrophoresis result after the first amplification of 8 virus strains;

[0017] Figure 2 This is the electrophoresis result after the second amplification of 8 virus strains;

[0018] Figure 3 It is the result of the purity test of mRNA molecules of 8 strains of viruses after transcription;

[0019] Figure 4 These are the results of in vitro expression of mRNA of 8 strains of viruses after transfection into cells;

[0020] Figure 5 It is the level of IgG antibodies specific to the novel coronavirus BA.5.1 strain in mice after vaccination;

[0021] Figure 6 It is the level of specific neutralizing antibodies against the novel coronavirus BA.5.1 strain in mice after vaccination;

[0022] Figure 7 It is the result of Zika virus amplification. DETAILED DESCRIPTION

[0023] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0024] The first aspect of the present invention provides a method for preparing an mRNA vaccine, the method comprising:

[0025] (1) amplifying the target gene by a first polymerase chain reaction and an optional second polymerase chain reaction to obtain an amplified product;

[0026] (2) transcribing the amplified product in vitro to obtain mRNA;

[0027] (3) capping and tailing the mRNA to obtain modified mRNA;

[0028] (4) assembling the modified mRNA with the vector;

[0029] Wherein, the final concentration of the upstream primer and the downstream primer in the amplification system is independently less than or equal to 5 μM, and can be 0.1 μM, 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM, 1 μM, 1.1 μM, 1.2 μM, 1.3 μM, 1.4 μM, 1.5 μM, 1.6 μM, 1.7 μM, 1.8 μM, 1.9 μM, 2 μM, 2.1 μM, 2.2 μM, 2.3 μM, 2.4 μM, 2.5 μM, 2.6 μM, 2.7 μM, 2.8 μM, 2.9 μM, 3.0 μM, 3.1 μM, 3.2 μM, 3.3 μM, 3.4 μM, 3.5 μM, 3.6 μM, 3.7 μM, 3.8 μM, 3.9 μM, 4. The range formed by any two of the above values ​​is preferably 0.5-2 μM, more preferably 0.8-1.2 μM.

[0030] In the present invention, the sequence of the upstream primer is shown as SEQ ID NO: 1; preferably, the sequence of the downstream primer is shown as SEQ ID NO: 2.

[0031] SEQ ID NO: 1 is:

[0032] TAATACGACTCACTATAGGCTTGTTCTTTTTTGCAGAAGCTCAGAATAA

[0033] ACGCTCAACTTTGGCGCCGCCACCATGGACTGGACCTGGATTCTCTTC

[0034] TTGGTGGCAGCAGCCACGCGAGTCCACTCCAGAGTHCAACCAACHG

[0035] SEQ ID NO: 2 is:

[0036] CTAGTGCCGCCCACTCAGACTTTATTCAAAGACCACGGGGGTACGGGT

[0037] GCAGGAAGGGGAGGAGGGGCTGGGGGGAGGCCCAAGGGGCAAGAAG

[0038] CATGGCCACCGAGGCTCCAGCCTAGAATTCTTATCAGAAHTTGACACA

[0039] TTT

[0040] The inventors of the present invention have discovered that when the upstream primer of the first polymerase chain reaction is as shown in SEQ ID NO: 1 and the sequence of the downstream primer is as shown in SEQ ID NO: 2, when the primers are long, primer dimers are easily formed, resulting in the inability of the primers to bind to the target fragment, resulting in amplification failure. However, amplification can be successfully performed within the primer concentration range of the present application, and the obtained amplification product can be successfully transcribed in vitro.

[0041] In the present invention, the reagents in the amplification system are commonly used by those skilled in the art for PCR, and except for the primer concentration, the concentrations of the other reagents are commonly used by those skilled in the art for PCR.

[0042] Preferably, the conditions of the first polymerase chain reaction include: the first stage: the temperature is 95-100°C, the time is 1.5-2.5min; the second stage: first at 95-100°C for 12-18s, then at 50-60°C for 12-18s, and then at 68-75°C for 0.7-1.3min; the cycle is 35-40 times; the third stage: the temperature is 68-75°C, the time is 1.5-2.5min. Then the mixture is stored at 3-5°C.

[0043] In the present invention, the primer contains a sequence required for in vitro transcription that can successfully transcribe the target gene. Preferably, the sequence required for in vitro transcription includes at least one of a promoter, a 5'UTR sequence, a 3'UTR sequence, and a signal peptide sequence. More preferably, the promoter is a T7 promoter. Further preferably, the sequence required for in vitro transcription is located at the 5' end of the upstream primer and the downstream primer. Preferably, the in vitro transcription sequence in the upstream primer includes a promoter, a 5'UTR sequence, and a signal peptide sequence. More preferably, the in vitro transcription sequence in the downstream primer includes a 3'UTR sequence. Further more preferably, the 5'-3' connection order of the upstream primer is: the promoter, the 5'UTR sequence, the signal peptide sequence, and the complementary sequence to the target gene are connected in sequence; the 5'-3' connection order of the downstream primer is: the 3'UTR and the complementary sequence to the target gene are connected in sequence.

[0044] More preferably, the sequence of the promoter may be as shown in positions 1 to 19 of SEQ ID NO:1.

[0045] More preferably, the 5'UTR sequence may be as shown in positions 20-62 of SEQ ID NO:1.

[0046] More preferably, the signal peptide sequence may be as shown in positions 63-126 of SEQ ID NO:1.

[0047] More preferably, the 3'UTR sequence may be as shown in positions 1-118 of SEQ ID NO:2.

[0048] More preferably, there may be a restriction site and a stop codon between the 3'UTR and the 5' end of the downstream primer. The sequence of the restriction site may be as shown in positions 119-124 of SEQ ID NO: 2, and the stop codon may be as shown in positions 125-130 of SEQ ID NO: 2.

[0049] In the present invention, the target gene is a gene encoding a viral antigen protein. The antigen protein can induce the production of specific IgG antibodies and neutralizing antibodies in animals. Preferably, the antigen protein is a surface glycoprotein receptor binding domain; more preferably, when the sequence of the upstream primer can be as shown in SEQ ID NO: 1 and the sequence of the downstream primer can be as shown in SEQ ID NO: 2, the virus can be a coronavirus and / or a β-coronavirus; further preferably, the coronavirus includes at least one of a novel coronavirus, a pangolin coronavirus and a bat-like coronavirus.

[0050] Preferably, the virus includes at least one of the original strain of the new coronavirus, B.1.1.7 strain, B.1.351 strain, B.1.617.2 strain, BA.1 strain, BA.2.1 strain, BA.5.1 strain, pangolin coronavirus GD1 strain and bat coronavirus RaTG13 strain.

[0051] In the present invention, the target gene is a DNA molecule that can transcribe mRNA, and the upstream primer and the downstream primer refer to the shortest nucleotide fragment (usually 15-30 bp) that can amplify the target gene by PCR.

[0052] The inventors of the present invention have found that the sequence required for in vitro transcription in the upstream primer is shown in positions 1-126 of SEQ ID NO: 1, and the sequence required for in vitro transcription in the downstream primer is shown in positions 1-130 of SEQ ID NO: 2, which are more likely to achieve successful amplification when combined with the primer concentration range defined by the present invention.

[0053] In the present invention, H in the above sequence is a degenerate base, which can be A / T / C, preferably a mixture of H=A, H=T and H=C, preferably, the molar ratio of H=A, H=T and H=C is 1:0.8-1.2:1.8-1.2.

[0054] In the present invention, in order to make the target gene more easily amplified successfully, a second polymerase chain reaction can be optionally performed, the primers and system used in the first polymerase chain reaction are as described above, and a first amplification product with a sequence required for in vitro transcription is obtained, and then a second polymerase chain reaction is performed using the first amplification product as a template to obtain an amplification product. Preferably, the upstream primer sequence of the second polymerase chain reaction is shown in SEQ ID NO: 1, positions 1-33, and the downstream primer sequence is shown in SEQ ID NO: 2, positions 1-31. More preferably, the final concentrations of the upstream primer and the downstream primer of the second polymerase chain reaction in the amplification system are independently 8-12 μM.

[0055] In the present invention, the reagents and concentrations in the second polymerase chain reaction system are commonly used reagents for PCR by those skilled in the art. The conditions of the second polymerase chain reaction are the same as those of the first polymerase chain reaction, and will not be described in detail here.

[0056] In the present invention, the capping and tailing methods are common mRNA capping and tailing methods in the art.

[0057] In the present invention, the carrier is any common carrier that can encapsulate mRNA and release mRNA in an animal body, preferably a lipid nanoparticle.

[0058] In the present invention, the amplified product, mRNA and modified mRNA can be purified.

[0059] In the present invention, the purified mRNA (with a purity exceeding 60%) can be subjected to a capping reaction, and the mRNA capping product and the mRNA tailing product can be purified.

[0060] In the present invention, the amplification product is purified by a common gel recovery purification method.

[0061] In the present invention, the purification method of the mRNA, mRNA capping product and mRNA tailing product is a common purification method in the art, preferably lithium chloride (LiCl) purification. Preferably, the purification method is specifically: 1. Add 1 / 2 of the reaction volume of the product (transcription product, mRNA capping product or mRNA tailing product) pre-cooled LiCl solution, and place it at -20°C for more than half an hour; 2. Centrifuge at 13000-15000g for 10-20min, and discard the supernatant; 3. Add 65-75% by weight ethanol, wash the precipitate, centrifuge at 13000-15000g for 1.5-2.5min, and discard the supernatant; 4. Repeat step "3"; 5. Add nuclease-free water to dissolve the precipitate.

[0062] The second aspect of the present invention provides an mRNA vaccine prepared by the above method.

[0063] The present invention will be described in detail below through examples.

[0064] Example

[0065] (1) Conservative primer design

[0066] MEGA 11 was used to compare the nucleic acid sequences encoding the receptor binding domain (RBD) of the original strain of the new coronavirus (WT), alpha strain (B.1.1.7), beta strain (B.1.351), delta strain (B.1.617.2), BA.1, BA.2.1, and BA.5.1 subtypes of the Omicron strain (B.1.1.529), pangolin coronavirus GD1 strain, and bat coronavirus RaTG13 strain. The primer pairs used in the first PCR were designed at both ends of the sequence, and degenerate bases were incorporated when designing primers at non-conserved sites. The primer pair used in the first PCR included T7 promoter, 5'UTR and 3'UTR sequences. The upstream primer sequence of the primer pair is shown in SEQ ID NO: 1 (Quick-F1), and the downstream primer sequence is shown in SEQ ID NO: 2 (Quick-R1). At the same time, the primer pair used in the second PCR is designed to amplify the amplification product containing the above-mentioned RNA element. The upstream primer sequence of the primer pair used in the second PCR is shown in SEQ ID NO: 1, positions 1-33 (Quick-F2), and the downstream primer sequence is shown in SEQ ID NO: 2, positions 1-31 (Quick-R2), wherein 1 / 3 of the H positions are A, 1 / 3 are T, and 1 / 3 are C.

[0067] (2) Amplification of target sequence

[0068] First, the viral RNA was reverse transcribed into cDNA using RT-PCR (reverse transcription using random primers will inevitably generate cDNA molecules of different sizes, which contain the target sequence). The cDNA or plasmid containing the target sequence was amplified under the condition of Quick-F1 and Quick-R1 concentration of 1 μM. The amplification procedure (2×Q5 high-fidelity enzyme was purchased from NEB, and the plasmid was synthesized by Sangon Biotechnology Co., Ltd.) is shown in Table 1.

[0069] Table 1

[0070]

[0071]

[0072] The amplified target product was identified by 1% agarose gel electrophoresis, and the amplified product was recovered and purified by gel recovery method (gel recovery kit purchased from Promega). The amplification results are shown in Figure 1 The results showed that the target sequence was successfully amplified. After gel recovery, the target band was single and the sequencing result was correct.

[0073] (3) Preparation of in vitro transcription template

[0074] The purified product of step (2) was used as a template, and the above fragment was amplified under the condition of Quick-F2 and Quick-R2 concentration of 10 μM to prepare an in vitro transcription template. The amplification program (2×Q5 high-fidelity enzyme purchased from NEB) is shown in Table 2.

[0075] Table 2

[0076]

[0077] The amplified target product was identified by 1% agarose gel electrophoresis, and the product was recovered and purified by gel recovery method (gel recovery kit purchased from Promega), and the sequence of the amplified product was sequenced. The results are as follows Figure 2 After gel recovery, the target band was single and the sequencing result was correct.

[0078] (4) Preparation of mRNA stock solution

[0079] The purified product in step (3) was used as a template for in vitro transcription. The in vitro transcription system (reagents purchased from Novozyme Biotechnology Co., Ltd.) is shown in Table 3. The in vitro transcription product was purified (purification methods were all lithium chloride purification, and the specific operations were as follows: 1. Add 1 / 2 of the volume of the in vitro transcription reaction volume of pre-cooled LiCl solution and place at -20°C for more than half an hour; 2. Centrifuge at 14000g for 15 minutes and discard the supernatant; 3. Add 70 wt% ethanol, wash the precipitate, centrifuge at 14000g for 2 minutes, and discard the supernatant; 4. Repeat step "3"; 5. Add an appropriate amount of nuclease-free water to dissolve the precipitate.), and the RNA molecule purity was tested by a bioanalyzer. The RNA molecule purity test results are shown in Figure 3 The mRNA with a purity of more than 60% was subjected to the next step of capping reaction. The mRNA capping system (reagents purchased from Novazon Biotech Co., Ltd.) is shown in Table 4. The capped product was purified (the purification method is shown in the above-mentioned in vitro transcription product purification method) and then tailed. The mRNA capping system (reagents purchased from Novazon Biotech Co., Ltd.) is shown in Table 5.

[0080] Table 3

[0081]

[0082] Table 4

[0083]

[0084]

[0085] Table 5

[0086]

[0087] (5) Identification of mRNA expression in vitro

[0088] HEK293T cells were transfected with 2 μg / well, and the supernatant was collected 48 hours after transfection, and the mRNA expression was detected by Western Blot. Figure 4 , the results showed that mRNA was successfully expressed.

[0089] (6) Evaluation of the ability of mRNA-LNP to induce humoral immunity in mice

[0090] 1) Preparation of mRNA-LNP:

[0091] mRNA was mixed with lipid nanoparticles (purchased from Abogen Biotech Co., Ltd.), and the preparation method was referenced in: Zhang et al. A Thermostable mRNA Vaccine against COVID-19. Cell, 2020, 182: 1271-1283.

[0092] 2) Injection culture: 6-week-old Balb / c mice were immunized with mRNA-LNP at a dose of 10 μg by intramuscular injection, and boosted immunization was performed 14 days after the initial immunization. Blood was collected through the ophthalmic venous plexus 14 and 28 days after the initial immunization, and the serum was separated for IgG antibody and neutralizing antibody detection.

[0093] 3) ELISA to detect IgG antibody levels: Dissolve the RBD protein of the BA.5 subtype of the novel coronavirus Omicron strain to 100 μg / ml, dilute it in the coating solution at 1:500, add 50 μl to each well of the ELISA-specific 96-well plate for coating, and incubate at 4°C overnight; the next day, discard the coating solution, wash 5 times with PBST, add 100 μl of 5% skim milk powder (blocking solution) to each well, and block at 37°C for 2h; discard the blocking solution, wash 5 times with PBST; dilute the inactivated serum twice with the blocking solution, The diluted serum was added to the coated plate at 100 μl per well and incubated at 37°C for 1 hour; the primary antibody was discarded, and the plate was washed 5 times with PBST. Then, the HRP-labeled secondary antibody was diluted at a ratio of 1:10000. The dilution solution was PBS containing 5% by weight skimmed milk powder. 100 μl was added to each well and incubated at 37°C for 1.5 hours; the secondary antibody was then discarded, washed 5 times with PBST, and finally, TMB solution was added. The color was developed at room temperature for 10 minutes. After the color development was completed, 50 μl of 5% by weight sulfuric acid (stop solution, purchased from Solebow Biotechnology Co., Ltd.) was added to each well to terminate the reaction; the OD 450 value was detected using an enzyme reader. A blank control well was set on each plate, and 2.1 times of the blank control well was used as the cutoff value. A value higher than the cutoff value was considered positive, and a value lower than the cutoff value was considered negative. The maximum dilution multiple of the positive result was the dilution endpoint. The placebo group was LNP without mRNA encapsulation. Results are shown in Figure 5 The results showed that after two doses of mRNA vaccine immunization, antigen-specific IgG antibodies can be effectively induced in mice, and after booster immunization, the IgG antibody level in the immunized group was significantly higher than that in the placebo group.

[0094] 4) Neutralization test of neutralizing antibodies: In a 96-well plate, the inactivated serum was diluted 3 times and 50 μl of 1.3×10 4 TCID 50 / ml pseudovirus expressing the surface glycoprotein of the new coronavirus BA.4, incubated at 37°C for 1 h, and added 100 μl of a 3.5×10 5 Huh 7 cell suspension of 10 cells / ml. After incubation at 37°C for 24 hours, discard 150 μl of supernatant, add 100 μl of luciferase substrate, color at room temperature in the dark for 2 minutes, mix with a spray gun, transfer 100 μl to a dedicated white opaque 96-well plate, and read the fluorescence value with GloMax. Calculate the neutralizing antibody level. The placebo group is LNP without mRNA encapsulation. The results are shown in Figure 6 The results showed that two injections of mRNA vaccine effectively induced the production of neutralizing antibodies in mice, and the level of neutralizing antibodies was significantly higher than that in the placebo group.

[0095] Comparative Example

[0096] The primers according to the embodiment are used to amplify Zika virus (ZIKV), and the amplification results are as follows: Figure 7 As shown, the results showed that the amplification was not successful.

[0097] The results show that by using the method of the present invention, there is no need to clone the target gene into a vector and prepare a linearized product, and the vaccine can be successfully prepared in a short time, and the production of antigen-specific IgG antibodies and neutralizing antibodies can be successfully induced in experimental animals.

[0098] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.

Claims

1. A method for preparing an mRNA vaccine, characterized in that: The method comprises: (1) amplifying the target gene by a first polymerase chain reaction and an optional second polymerase chain reaction to obtain an amplified product; (2) transcribing the amplified product in vitro to obtain mRNA; (3) capping and tailing the mRNA to obtain modified mRNA; (4) assembling the modified mRNA with the vector; Wherein, the final concentrations of the upstream primer and the downstream primer in the amplification system are independently less than or equal to 5 μM.

2. The method according to claim 1, wherein: The final concentrations of the upstream primer and the downstream primer in the amplification system are independently 0.5-2 μM, more preferably 0.8-1.2 μM.

3. The method according to claim 1 or 2, wherein: The sequence of the upstream primer is shown in SEQ ID NO: 1; Preferably, the sequence of the downstream primer is as shown in SEQ ID NO:

2.

4. The method according to claim 1 or 2, wherein: The conditions of the first polymerase chain reaction include: the first stage: the temperature is 95-100°C, the time is 1.5-2.5 minutes; the second stage: first at 95-100°C for 12-18 seconds, then at 50-60°C for 12-18 seconds, and then at 68-75°C for 0.7-1.3 minutes; the cycle is 35-40 times; the third stage: the temperature is 68-75°C, the time is 1.5-2.5 minutes; And / or, the conditions of the second polymerase chain reaction include: first stage: temperature of 95-100°C, time of 1.5-2.5min; second stage: first at 95-100°C for 12-18s, then at 50-60°C for 12-18s, and then at 68-75°C for 0.7-1.3min; cycle 35-40 times; third stage: temperature of 68-75°C, time of 1.5-2.5min.

5. The method according to claim 1 or 2, wherein: The upstream primer sequence of the second polymerase chain reaction is shown in SEQ ID NO: 1, positions 1-33, and the downstream primer sequence is shown in SEQ ID NO: 2, positions 1-31; And / or, the final concentrations of the upstream primer and the downstream primer of the second polymerase chain reaction in the amplification system are independently 8-12 μM.

6. The method according to claim 1 or 2, wherein: The carrier is lipid nanoparticle.

7. The method according to claim 1 or 2, wherein: The target gene is a gene encoding a viral antigen protein, and the antigen protein is a surface glycoprotein receptor binding domain.

8. The method according to claim 7, wherein: The virus is a coronavirus and / or a beta-coronavirus; And / or, the coronavirus includes at least one of a novel coronavirus, a pangolin coronavirus and a bat coronavirus.

9. The method according to claim 7, wherein: The virus includes at least one of the original strain of the new coronavirus, B.1.1.7 strain, B.1.351 strain, B.1.617.2 strain, BA.1 strain, BA.2.1 strain, BA.5.1 strain, pangolin coronavirus GD1 strain and bat-like coronavirus RaTG13 strain.

10. The mRNA vaccine prepared by the method described in claims 1-9.